What Researchers Did
Researchers conducted a systematic review and meta-analysis of twelve studies to evaluate how well hyperbaric oxygen therapy (HBOT) works and its safety for treating central retinal artery occlusion (CRAO).
What They Found
The analysis showed that HBOT was beneficial for CRAO, with a pooled odds ratio of 0.47 (95% CI: 0.26-0.87; p = 0.02). Visual improvement was greater when HBOT started within 12 hours of CRAO onset, while delayed treatment showed less consistent benefits. Importantly, the rates of adverse events were similar between HBOT and non-HBOT groups (OR = 0.70; 95% CI: 0.43-1.16; p = 0.17).
What This Means for Canadian Patients
For Canadian patients experiencing central retinal artery occlusion, this study suggests that hyperbaric oxygen therapy could be a promising treatment option. The findings highlight the importance of receiving HBOT quickly, ideally within 12 hours of symptoms, to achieve the best visual recovery and potentially improve vision outcomes.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
A limitation of this meta-analysis was the substantial variability found among the included studies, which could influence the overall findings.